After FDA rejection, Lilly's ulcerative colitis drug Omvoh picks up support from England's NICE
Fierce Pharma
SEPTEMBER 21, 2023
Even after Eli Lilly missed its first swing at the lucrative U.S. market with ulcerative colitis drug mirikizumab, the company’s launch is gaining steam overseas. | Lilly's mirikizumab is one of several launches the company is counting on for growth in the near term.
Let's personalize your content